Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet 7/30 to discuss the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by FDA and GlaxoSmithKline. The meeting will take place from 8 a.m. to 5 p.m. at the Holiday Inn Gaithersburg, 2 Montgomery Village Ave., Gaithersburg, MD. Contact Cathy A. Miller, (301) 827-7001. To view this notice, click here.